Alpha-adrenergic agonist

Classes

Although complete selectivity between receptor agonism is rarely achieved, some agents have partial selectivity. NB: the inclusion of a drug in each category just indicates the activity of the drug at that receptor, not necessarily the selectivity of the drug (unless otherwise noted).

α₁ agonist

Main article: Alpha-1 adrenergic receptor#agonist

α1 agonist: stimulates phospholipase C activity. (vasoconstriction and mydriasis; used as vasopressors, nasal decongestants and during eye exams). Selected examples are:

• Adrenoswitch-1 (photoswitchable partial α1 agonist and light-controlled mydriatic)
• Methoxamine
• Midodrine
• Metaraminol
• Phenylephrine
• Amidephrine
• Sdz-nvi-085 [104195-17-7].

α₂ agonist

Main article: Alpha-2 adrenergic receptor#Agonists

α2 agonist: inhibits adenylyl cyclase activity, reduces brainstem vasomotor center-mediated CNS activation; used as antihypertensive, sedative & treatment of opiate dependence and alcohol withdrawal symptoms). Selected examples are:

• Agmatine
• Brimonidine
• Clonidine (mixed alpha2-adrenergic and imidazoline-I1 receptor agonist)
• Dexmedetomidine
• Fadolmidine
• Guanfacine, (preference for alpha2A-subtype of adrenoceptor)
• Guanabenz (most selective agonist for alpha2-adrenergic as opposed to imidazoline-I1)
• Guanoxabenz (metabolite of guanabenz)
• Xylazine (not approved for human use)
• Tizanidine
• Methyldopa
• Methylnorepinephrine
• Norepinephrine
• (R)-3-nitrobiphenyline, an α2C selective agonist as well as a weak antagonist at the α and α subtypes.
• Amitraz
• Detomidine
• Lofexidine, an α2A adrenergic receptor agonist.
• Medetomidine, an α2 adrenergic agonist.
• Tasipimidine

Nonspecific agonist

Nonspecific agonists act as agonists at both alpha-1 and alpha-2 receptors.

• Xylometazoline
• Oxymetazoline
• Apraclonidine
• Cirazoline
• Epinephrine

Undetermined/unsorted

The following agents are also listed as agonists by MeSH.

• Ergotamine
• Etilefrine
• Indanidine
• Mephentermine
• Metaraminol
• Methoxamine
• Mivazerol
• Naphazoline
• Norfenefrine
• Octopamine
• Phenylpropanolamine
• Propylhexedrine
• Rilmenidine
• Romifidine
• Synephrine
• Talipexole

Clinical significance

Alpha-adrenergic agonists, more specifically the auto receptors of alpha 2 neurons, are used in the treatment of glaucoma by decreasing the production of aqueous fluid by the ciliary bodies of the eye and also by increasing uveoscleral outflow. Medications such as clonidine and dexmedetomidine target pre-synaptic auto receptors, therefore leading to an overall decrease in norepinephrine which clinically can cause effects such as sedation, analgesia, lowering of blood pressure and bradycardia. There is also low quality evidence that they can reduce shivering post operatively.

The reduction of the stress response caused by alpha 2 agonists were theorised to be beneficial peri operatively by reducing cardiac complications, however this has shown not to be clinically effective as there was no reduction in cardiac events or mortality but there was an increased incidence of hypotension and bradycardia.

Alpha-2 adrenergic agonists are sometimes prescribed alone or in combination with stimulants to treat ADHD.

References

References

1. (February 2021). "Adrenergic Modulation With Photochromic Ligands". Angewandte Chemie.
2. (September 1990). "The alpha 1-agonist phenylephrine inhibits voltage-gated Ca2(+)-channels in vascular smooth muscle cells of rabbit ear artery". Pflügers Archiv.
3. (June 1989). "Pressor effects of the alpha 2-adrenoceptor agonist B-HT 933 in anaesthetized and haemorrhagic rats: comparison with the haemodynamic effects of amidephrine". British Journal of Pharmacology.
4. (December 2006). "The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)". Behavioral and Brain Functions.
5. (April 2000). "Interactions between phenylephrine, clonidine and xylazine in rat and rabbit aortas". Methods and Findings in Experimental and Clinical Pharmacology.
6. (June 2004). "Perioperative use of selective alpha-2 agonists and antagonists in small animals". The Canadian Veterinary Journal.
7. (August 2007). "Alpha2-adrenoreceptors profile modulation. 3.1 (R)-(+)-m-nitrobiphenyline, a new efficient and alpha2C-subtype selective agonist". Journal of Medicinal Chemistry.
8. (November 2010). "Fruitful adrenergic α(2C)-agonism/α(2A)-antagonism combination to prevent and contrast morphine tolerance and dependence". Journal of Medicinal Chemistry.
9. (1984). "Amitraz-induced delay of gastrointestinal transit in mice: Mediated by α2-adrenergic receptors.". Drug Development Research.
10. "Detomidine {{!}} α2-adrenergic Agonist {{!}} MedChemExpress".
11. "Press Announcements - FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults".
12. (November 2003). "A review of the physiological effects of alpha2-agonists related to the clinical use of medetomidine in small animal practice". The Canadian Veterinary Journal.
13. (December 2010). "Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline". Fundamental & Clinical Pharmacology.
14. "Goodman & Gilman's The Pharmacological Basis of Therapeutics".
15. (September 1995). "Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes". British Journal of Pharmacology.
16. (July 1982). "Receptor interactions of imidazolines. IX. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist". The Journal of Pharmacology and Experimental Therapeutics.
17. (2008). "Illustrated Pharmacology Memory Cards: PharMnemonics". Minireview.
18. {{MeshPharmaList. 82000316
19. (August 2015). "Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia". The Cochrane Database of Systematic Reviews.
20. (March 2018). "Alpha-2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surgery". The Cochrane Database of Systematic Reviews.
21. (2022). "New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder". Springer International Publishing.